07/09/2026 FDA withdraws Krazati’s colorectal cancer indication after KRYSTAL‑10 fails to confirm survival benefit FDA withdraws Krazati’s colorectal cancer indication after KRYSTAL‑10 fails to confirm survival benefit (Ref) The FDA has finalized the withdrawal of Bristol Myers Squibb’s Krazati (adagrasib; KRAS inhibitor) for colorectal cancer, citing lack of confirmed clinical benefit after the KRYSTAL‑10 Phase III trial failed to meet survival endpoints Krazati had received

02/07/2025 Lynozyfic received accelerated approval from the US FDA for R/R Multiple Myeloma (Ref) Regeneron Pharmaceuticals announced that the US FDA granted accelerated approval for linvoseltamab-gcpt (Lynozyfic; BCMA x CD3 bispecific antibody) for patients with relapsed or refractory (R/R) multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti‑CD38 monoclonal antibody The accelerated a